Clinical Trials Browser

Not yet recruiting × INDUSTRY × Cisplatin × Clear all

NCT07524257 2026-04-13

ResQ1010-NSCLC: NAI + Chemoimmunotherapy vs Chemoimmunotherapy for First-Line Advanced/Metastatic NSCLC

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07486817 2026-03-23

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

Phase 2 Not yet recruiting

Lung Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT07383116 2026-02-03

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Phase 3 Not yet recruiting

Non Squamous Non-small Cell Lung Cancer

NCT07365319 2026-01-26

TeLuRide-008

Phase 2/3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT06724042 2025-12-10

Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors

Phase 1 Not yet recruiting

Neoplasm Metastasis

NCT07256509 2025-12-05

A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07151872 2025-09-03

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Phase 2 Not yet recruiting

Gastrointestinal

CLDN18.2-positive Advanced Biliary Tract Cancer

NCT07138001 2025-08-22

Phase 2 Clinical Trial of KH617

Phase 2 Not yet recruiting

Glioblastoma

NCT07109531 2025-08-07

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06970782 2025-05-21

KYLIN-3

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06963502 2025-05-09

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors

Phase 1 Not yet recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Phase 1/2 Not yet recruiting

Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06594874 2024-09-19

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

Phase 1 Not yet recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06514027 2024-07-23

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06446388 2024-06-06

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Phase 2 Not yet recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT06380348 2024-04-23

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05767892 2023-04-05

YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Phase 3 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Phase 3 Not yet recruiting

Recurrence

NCT05715840 2023-02-08

Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)

Phase 3 Not yet recruiting

Recurrence